Do analysts recommend LIAN or TVRD?

Tvardi Therapeutics has a consensus target price of $18.00, indicating a potential upside of 847.37%. Given Tvardi Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Tvardi Therapeutics is more favorable than LianBio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LianBio 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Tvardi Therapeutics 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.78

Is LIAN or TVRD more profitable?

LianBio's return on equity of -33.17% beat Tvardi Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets LianBio N/A -33.17% -30.19% Tvardi Therapeutics N/A -64.17% -43.90%

Do analysts recommend VYNE or LIAN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score VYNE Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 LianBio 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is VYNE or LIAN more profitable?

LianBio has a net margin of 0.00% compared to VYNE Therapeutics' net margin of -4,726.21%. LianBio's return on equity of -33.17% beat VYNE Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets VYNE Therapeutics -4,726.21% -70.42% -63.46% LianBio N/A -33.17% -30.19%

Do analysts rate LIAN or LPCN?

Lipocine has a consensus target price of $15.00, suggesting a potential upside of 610.90%. Given Lipocine's stronger consensus rating and higher probable upside, analysts plainly believe Lipocine is more favorable than LianBio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LianBio 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Lipocine 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has better earnings and valuation, LIAN or LPCN?

Lipocine has higher revenue and earnings than LianBio. Lipocine is trading at a lower price-to-earnings ratio than LianBio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LianBio N/A N/A -$110.29M -$0.81 N/A Lipocine $1.98M 8.78 -$9.63M -$1.79 N/A

Is LIAN or LPCN more profitable?

LianBio has a net margin of 0.00% compared to Lipocine's net margin of -755.39%. LianBio's return on equity of -33.17% beat Lipocine's return on equity. Company Net Margins Return on Equity Return on Assets LianBio N/A -33.17% -30.19% Lipocine -755.39% -64.75% -57.62%

Do analysts recommend LIAN or MDCX?

Medicus Pharma has a consensus price target of $9.00, suggesting a potential upside of 3,113.14%. Given Medicus Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Medicus Pharma is more favorable than LianBio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LianBio 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Medicus Pharma 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Which has preferable valuation and earnings, LIAN or MDCX?

Medicus Pharma is trading at a lower price-to-earnings ratio than LianBio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LianBio N/A N/A -$110.29M -$0.81 N/A Medicus Pharma N/A N/A -$35.46M -$2.68 N/A

Is LIAN or MDCX more profitable?

LianBio's return on equity of -33.17% beat Medicus Pharma's return on equity. Company Net Margins Return on Equity Return on Assets LianBio N/A -33.17% -30.19% Medicus Pharma N/A -16,319.59% -263.24%

Do analysts prefer LIAN or CTXR?

Citius Pharmaceuticals has a consensus target price of $5.00, suggesting a potential upside of 561.73%. Given Citius Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Citius Pharmaceuticals is more favorable than LianBio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LianBio 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Citius Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Which has stronger earnings & valuation, LIAN or CTXR?

Citius Pharmaceuticals is trading at a lower price-to-earnings ratio than LianBio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LianBio N/A N/A -$110.29M -$0.81 N/A Citius Pharmaceuticals N/A N/A -$37.43M -$2.13 N/A

Is LIAN or CTXR more profitable?

LianBio's return on equity of -33.17% beat Citius Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets LianBio N/A -33.17% -30.19% Citius Pharmaceuticals N/A -61.09% -35.36%

LianBio (LIAN) Competitors

$0.04 0.00 (0.00%)

As of 08/13/2026

Compare

LIAN vs. TVRD, VYNE, LPCN, MDCX, and CTXR

Should you buy LianBio stock or one of its competitors? LianBio's main competitors and comparable companies include Tvardi Therapeutics (TVRD), VYNE Therapeutics (VYNE), Lipocine (LPCN), Medicus Pharma (MDCX), and Citius Pharmaceuticals (CTXR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does LianBio compare to Tvardi Therapeutics?

LianBio (NASDAQ:LIAN) and Tvardi Therapeutics (NASDAQ:TVRD) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, institutional ownership, risk and profitability.

74.8% of LianBio shares are owned by institutional investors. Comparatively, 44.7% of Tvardi Therapeutics shares are owned by institutional investors. 7.6% of LianBio shares are owned by insiders. Comparatively, 7.4% of Tvardi Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

LianBio's return on equity of -33.17% beat Tvardi Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LianBio	N/A	-33.17%	-30.19%
Tvardi Therapeutics	N/A	-64.17%	-43.90%

Tvardi Therapeutics has higher revenue and earnings than LianBio. Tvardi Therapeutics is trading at a lower price-to-earnings ratio than LianBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LianBio	N/A	N/A	-$110.29M	-$0.81	N/A
Tvardi Therapeutics	$7.14M	2.50	-$18.21M	-$3.10	N/A

In the previous week, Tvardi Therapeutics had 5 more articles in the media than LianBio. MarketBeat recorded 5 mentions for Tvardi Therapeutics and 0 mentions for LianBio. LianBio's average media sentiment score of 0.00 beat Tvardi Therapeutics' score of -0.03 indicating that LianBio is being referred to more favorably in the media.

Company	Overall Sentiment
LianBio	Neutral
Tvardi Therapeutics	Neutral

LianBio has a beta of 0.23, indicating that its share price is 77% less volatile than the broader market. Comparatively, Tvardi Therapeutics has a beta of 0.39, indicating that its share price is 61% less volatile than the broader market.

Tvardi Therapeutics has a consensus target price of $18.00, indicating a potential upside of 847.37%. Given Tvardi Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Tvardi Therapeutics is more favorable than LianBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LianBio	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Tvardi Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Summary

Tvardi Therapeutics beats LianBio on 8 of the 15 factors compared between the two stocks.

How does LianBio compare to VYNE Therapeutics?

VYNE Therapeutics (NASDAQ:VYNE) and LianBio (NASDAQ:LIAN) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, profitability, earnings, institutional ownership and dividends.

VYNE Therapeutics has higher revenue and earnings than LianBio. VYNE Therapeutics is trading at a lower price-to-earnings ratio than LianBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VYNE Therapeutics	$570K	33.29	-$26.48M	-$0.38	N/A
LianBio	N/A	N/A	-$110.29M	-$0.81	N/A

LianBio has a net margin of 0.00% compared to VYNE Therapeutics' net margin of -4,726.21%. LianBio's return on equity of -33.17% beat VYNE Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
VYNE Therapeutics	-4,726.21%	-70.42%	-63.46%
LianBio	N/A	-33.17%	-30.19%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VYNE Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
LianBio	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

83.8% of VYNE Therapeutics shares are owned by institutional investors. Comparatively, 74.8% of LianBio shares are owned by institutional investors. 3.0% of VYNE Therapeutics shares are owned by insiders. Comparatively, 7.6% of LianBio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, VYNE Therapeutics had 1 more articles in the media than LianBio. MarketBeat recorded 1 mentions for VYNE Therapeutics and 0 mentions for LianBio. LianBio's average media sentiment score of 0.00 beat VYNE Therapeutics' score of -3.00 indicating that LianBio is being referred to more favorably in the news media.

Company	Overall Sentiment
VYNE Therapeutics	Very Negative
LianBio	Neutral

VYNE Therapeutics has a beta of 2, meaning that its share price is 100% more volatile than the broader market. Comparatively, LianBio has a beta of 0.23, meaning that its share price is 77% less volatile than the broader market.

Summary

VYNE Therapeutics beats LianBio on 7 of the 13 factors compared between the two stocks.

How does LianBio compare to Lipocine?

LianBio (NASDAQ:LIAN) and Lipocine (NASDAQ:LPCN) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

74.8% of LianBio shares are held by institutional investors. Comparatively, 9.1% of Lipocine shares are held by institutional investors. 7.6% of LianBio shares are held by insiders. Comparatively, 4.7% of Lipocine shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Lipocine had 2 more articles in the media than LianBio. MarketBeat recorded 2 mentions for Lipocine and 0 mentions for LianBio. Lipocine's average media sentiment score of 1.31 beat LianBio's score of 0.00 indicating that Lipocine is being referred to more favorably in the news media.

Company	Overall Sentiment
LianBio	Neutral
Lipocine	Positive

Lipocine has a consensus target price of $15.00, suggesting a potential upside of 610.90%. Given Lipocine's stronger consensus rating and higher probable upside, analysts plainly believe Lipocine is more favorable than LianBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LianBio	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Lipocine	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

LianBio has a beta of 0.23, suggesting that its share price is 77% less volatile than the broader market. Comparatively, Lipocine has a beta of 0.46, suggesting that its share price is 54% less volatile than the broader market.

Lipocine has higher revenue and earnings than LianBio. Lipocine is trading at a lower price-to-earnings ratio than LianBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LianBio	N/A	N/A	-$110.29M	-$0.81	N/A
Lipocine	$1.98M	8.78	-$9.63M	-$1.79	N/A

LianBio has a net margin of 0.00% compared to Lipocine's net margin of -755.39%. LianBio's return on equity of -33.17% beat Lipocine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LianBio	N/A	-33.17%	-30.19%
Lipocine	-755.39%	-64.75%	-57.62%

Summary

LianBio and Lipocine tied by winning 7 of the 14 factors compared between the two stocks.

How does LianBio compare to Medicus Pharma?

LianBio (NASDAQ:LIAN) and Medicus Pharma (NASDAQ:MDCX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, dividends, risk, earnings, analyst recommendations and valuation.

LianBio's return on equity of -33.17% beat Medicus Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LianBio	N/A	-33.17%	-30.19%
Medicus Pharma	N/A	-16,319.59%	-263.24%

Medicus Pharma has a consensus price target of $9.00, suggesting a potential upside of 3,113.14%. Given Medicus Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Medicus Pharma is more favorable than LianBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LianBio	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Medicus Pharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

In the previous week, Medicus Pharma had 6 more articles in the media than LianBio. MarketBeat recorded 6 mentions for Medicus Pharma and 0 mentions for LianBio. Medicus Pharma's average media sentiment score of 0.18 beat LianBio's score of 0.00 indicating that Medicus Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
LianBio	Neutral
Medicus Pharma	Neutral

74.8% of LianBio shares are held by institutional investors. 7.6% of LianBio shares are held by company insiders. Comparatively, 8.1% of Medicus Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Medicus Pharma is trading at a lower price-to-earnings ratio than LianBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LianBio	N/A	N/A	-$110.29M	-$0.81	N/A
Medicus Pharma	N/A	N/A	-$35.46M	-$2.68	N/A

LianBio has a beta of 0.23, suggesting that its stock price is 77% less volatile than the broader market. Comparatively, Medicus Pharma has a beta of 0.11, suggesting that its stock price is 89% less volatile than the broader market.

Summary

Medicus Pharma beats LianBio on 7 of the 13 factors compared between the two stocks.

How does LianBio compare to Citius Pharmaceuticals?

LianBio (NASDAQ:LIAN) and Citius Pharmaceuticals (NASDAQ:CTXR) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings, media sentiment and analyst recommendations.

Citius Pharmaceuticals is trading at a lower price-to-earnings ratio than LianBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LianBio	N/A	N/A	-$110.29M	-$0.81	N/A
Citius Pharmaceuticals	N/A	N/A	-$37.43M	-$2.13	N/A

LianBio's return on equity of -33.17% beat Citius Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LianBio	N/A	-33.17%	-30.19%
Citius Pharmaceuticals	N/A	-61.09%	-35.36%

In the previous week, Citius Pharmaceuticals had 6 more articles in the media than LianBio. MarketBeat recorded 6 mentions for Citius Pharmaceuticals and 0 mentions for LianBio. Citius Pharmaceuticals' average media sentiment score of 0.62 beat LianBio's score of 0.00 indicating that Citius Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
LianBio	Neutral
Citius Pharmaceuticals	Positive

74.8% of LianBio shares are held by institutional investors. Comparatively, 16.9% of Citius Pharmaceuticals shares are held by institutional investors. 7.6% of LianBio shares are held by insiders. Comparatively, 5.0% of Citius Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

LianBio has a beta of 0.23, suggesting that its share price is 77% less volatile than the broader market. Comparatively, Citius Pharmaceuticals has a beta of 1.03, suggesting that its share price is 3% more volatile than the broader market.

Citius Pharmaceuticals has a consensus target price of $5.00, suggesting a potential upside of 561.73%. Given Citius Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Citius Pharmaceuticals is more favorable than LianBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LianBio	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Citius Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Citius Pharmaceuticals beats LianBio on 7 of the 13 factors compared between the two stocks.

Get LianBio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LIAN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LIAN vs. The Competition

Export

Metric	LianBio	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$4.40M	$11.89B	$7.06B	$13.10B
Dividend Yield	N/A	2.70%	2.57%	10.45%
P/E Ratio	-0.05	775.15	269.06	25.28
Price / Sales	N/A	743.50	592.57	87.62
Price / Cash	N/A	66.45	70.48	50.90
Price / Book	0.02	11.60	12.91	6.24
Net Income	-$110.29M	$2.77B	$3.45B	$347.60M
7 Day Performance	N/A	0.17%	1.12%	1.07%
1 Month Performance	N/A	0.35%	1.79%	1.03%
1 Year Performance	N/A	161.52%	67.69%	20.77%

LianBio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LIAN LianBio	N/A	$0.04 flat	N/A	-20.7%	$4.40M	N/A	N/A	110
TVRD Tvardi Therapeutics	3.5979 of 5 stars	$2.00 -1.5%	$18.00 +800.0%	-92.5%	$19.04M	$7.14M	N/A	80	News Coverage Earnings Report Short Interest Decrease Gap Up
VYNE VYNE Therapeutics	0.2334 of 5 stars	$28.33 -0.8%	N/A	+63.0%	$18.98M	$570K	N/A	30	Negative News Earnings Report Gap Down High Trading Volume
LPCN Lipocine	2.778 of 5 stars	$2.17 +1.9%	$15.00 +591.2%	-31.6%	$17.56M	$1.98M	N/A	10	Gap Up
MDCX Medicus Pharma	2.235 of 5 stars	$0.30 -2.4%	$9.00 +2,932.3%	-83.1%	$17.22M	N/A	N/A	N/A	Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LIAN) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

LianBio (LIAN) Competitors

LIAN vs. TVRD, VYNE, LPCN, MDCX, and CTXR

How does LianBio compare to Tvardi Therapeutics?

Summary

How does LianBio compare to VYNE Therapeutics?

Summary

How does LianBio compare to Lipocine?

Summary

How does LianBio compare to Medicus Pharma?

Summary

How does LianBio compare to Citius Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LIAN vs. The Competition

LianBio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

LianBio (LIAN) Competitors

LIAN vs. TVRD, VYNE, LPCN, MDCX, and CTXR

How does LianBio compare to Tvardi Therapeutics?

Do institutionals and insiders believe in LIAN or TVRD?

Is LIAN or TVRD more profitable?

Which has stronger earnings and valuation, LIAN or TVRD?

Does the media refer more to LIAN or TVRD?

Which has more risk & volatility, LIAN or TVRD?

Do analysts recommend LIAN or TVRD?

Summary

How does LianBio compare to VYNE Therapeutics?

Which has preferable valuation and earnings, VYNE or LIAN?

Is VYNE or LIAN more profitable?

Do analysts recommend VYNE or LIAN?

Do institutionals & insiders hold more shares of VYNE or LIAN?

Does the media favor VYNE or LIAN?

Which has more risk and volatility, VYNE or LIAN?

Summary

How does LianBio compare to Lipocine?

Do insiders & institutionals hold more shares of LIAN or LPCN?

Does the media refer more to LIAN or LPCN?

Do analysts rate LIAN or LPCN?

Which has more volatility & risk, LIAN or LPCN?

Which has better earnings and valuation, LIAN or LPCN?

Is LIAN or LPCN more profitable?

Summary

How does LianBio compare to Medicus Pharma?

Is LIAN or MDCX more profitable?

Do analysts recommend LIAN or MDCX?

Does the media prefer LIAN or MDCX?

Do institutionals and insiders have more ownership in LIAN or MDCX?

Which has preferable valuation and earnings, LIAN or MDCX?

Which has more risk & volatility, LIAN or MDCX?

Summary

How does LianBio compare to Citius Pharmaceuticals?

Which has stronger earnings & valuation, LIAN or CTXR?

Is LIAN or CTXR more profitable?

Does the media prefer LIAN or CTXR?

Do insiders and institutionals have more ownership in LIAN or CTXR?

Which has more volatility & risk, LIAN or CTXR?

Do analysts prefer LIAN or CTXR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LIAN vs. The Competition

LianBio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools